Chen J. Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses. Microbes Infect. 2020;22(2):69–71.

Article  PubMed  PubMed Central  Google Scholar 

Ko JY, Danielson ML, Town M, Derado G, Greenlund KJ, Kirley PD, et al. Risk factors for coronavirus disease 2019 (COVID-19)–associated hospitalization: COVID-19–associated hospitalization surveillance network and behavioral risk factor surveillance system. Clin Infect Dis. 2021;72(11):e695-703.

Article  PubMed  Google Scholar 

Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383(25):2451–60.

Article  PubMed  Google Scholar 

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–42.

Article  PubMed  Google Scholar 

Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Epidemiol. 2020;35(12):1123–38.

Article  PubMed  PubMed Central  Google Scholar 

O’Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021;590(7844):140–5.

Article  ADS  PubMed  Google Scholar 

Gao Y-D, Ding M, Dong X, Zhang J-J, KursatAzkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428–55.

Article  PubMed  Google Scholar 

Boisson-Dupuis S, Bustamante J. Mycobacterial diseases in patients with inborn errors of immunity. Curr Opin Immunol. 2021;1(72):262–71.

Article  Google Scholar 

Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570.

Article  PubMed  PubMed Central  Google Scholar 

Bastard P, Michailidis E, Hoffmann HH, Chbihi M, Le Voyer T, Rosain J, et al. Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J Exp Med. 2021;218(4):e20202486.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Q, Pizzorno A, Miorin L, Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J Exp Med. 2022;219(11):e20220514.

Article  PubMed  PubMed Central  Google Scholar 

Gervais A, Rovida F, Avanzini MA, Croce S, Marchal A, Lin SC, et al. Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients. J Exp Med. 2023;220(9):e20230661.

Article  PubMed  PubMed Central  Google Scholar 

Bastard P, Gervais A, Le Voyer T, Philippot Q, Cobat A, Rosain J, et al. Human autoantibodies neutralizing type I IFNs: From 1981 to 2023. Immunological Reviews [Internet]. [cited 2024 Jan 22];n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/imr.13304.

Martinot M, Gravier S, Mohseni-Zadeh M, Fabien N, Casanova JL, Puel A, et al. Severe acute herpes virus type 2 primo-infection and its association with anti-type 1 interferon autoantibodies. Eur J Clin Microbiol Infect Dis. 2023;42(12):1531–5.

Article  PubMed  Google Scholar 

Zhang Q, Bastard P, Bolze A, Jouanguy E, Zhang SY, Cobat A, et al. Life-threatening COVID-19: Defective interferons unleash excessive inflammation. Med. 2020;1(1):14–20.

Article  PubMed  Google Scholar 

Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585.

Article  PubMed  PubMed Central  Google Scholar 

Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021;6(612):eabh2624.

Google Scholar 

van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med. 2021;13(612):eabh2624.

Article  PubMed  PubMed Central  Google Scholar 

Koning R, Bastard P, Casanova JL, Brouwer MC, van de Beek D, van Agtmael M, et al. Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med. 2021;47(6):704–6.

Article  PubMed  PubMed Central  Google Scholar 

Chauvineau-Grenier A, Bastard P, Servajean A, Gervais A, Rosain J, Jouanguy E, et al. Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital. J Clin Immunol. 2022;42(3):459–70.

Article  PubMed  PubMed Central  Google Scholar 

Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci USA. 2022;119(21):e2200413119.

Article  PubMed  PubMed Central  Google Scholar 

Vazquez SE, Bastard P, Kelly K, Gervais A, Norris PJ, Dumont LJ, et al. Neutralizing autoantibodies to type I interferons in COVID-19 convalescent donor plasma. J Clin Immunol. 2021;41(6):1169–71.

Article  PubMed  PubMed Central  Google Scholar 

Troya J, Bastard P, Planas-Serra L, Ryan P, Ruiz M, de Carranza M, et al. Neutralizing autoantibodies to type I IFNs in >10% of patients with severe COVID-19 pneumonia hospitalized in Madrid. Spain J Clin Immunol. 2021;41(5):914–22.

Article  PubMed  Google Scholar 

Released by National Health Commission & National Administration of Traditional Chinese Medicine on March 15 2022. Diagnosis and treatment protocol for COVID-19 patients (Trial Version 9). Health Care Sci. 2022;1(1):14–28.

Zhang Y, Song W, Chen S, Yuan Z, Yi Z. A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2. Antiviral Res. 2021;185:104974.

Article  PubMed  Google Scholar 

Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res. 2020;1(179):104811.

Article  Google Scholar 

Ling Y, Lu G, Liu F, Tan Y, Xu X, Wei D, et al. The Omicron BA.2.2.1 subvariant drove the wave of SARS-CoV-2 outbreak in Shanghai during spring 2022. Cell Discov. 2022;8(1):1–3.

Article  Google Scholar 

Lu G, Ling Y, Jiang M, Tan Y, Wei D, Jiang L, et al. Primary assessment of the diversity of Omicron sublineages and the epidemiologic features of autumn/winter 2022 COVID-19 wave in Chinese mainland. Front Med. 2023;17(4):758–67.

Article  PubMed  Google Scholar 

Fu Z, Liang D, Zhang W, Shi D, Ma Y, Wei D, et al. Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai. Front Med. 2023;17(3):562–75.

Article  PubMed  Google Scholar 

Philippot Q, Fekkar A, Gervais A, Le Voyer T, Boers LS, Conil C, et al. Autoantibodies neutralizing type I IFNs in the bronchoalveolar lavage of at least 10% of patients during life-threatening COVID-19 pneumonia. J Clin Immunol. 2023;43(6):1093–103.

Article  PubMed  PubMed Central  Google Scholar 

Eto S, Nukui Y, Tsumura M, Nakagama Y, Kashimada K, Mizoguchi Y, et al. Neutralizing type I interferon autoantibodies in Japanese patients with severe COVID-19. J Clin Immunol. 2022;42(7):1360–70.

Article  PubMed  PubMed Central  Google Scholar 

Abers MS, Rosen LB, Delmonte OM, Shaw E, Bastard P, Imberti L, et al. Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19. Immunol Cell Biol. 2021;99(9):917–21.

Article  PubMed  PubMed Central  Google Scholar 

Frasca F, Scordio M, Santinelli L, Gabriele L, Gandini O, Criniti A, et al. Anti-IFN-α/-ω neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity. Eur J Immunol. 2022;52(7):1120–8.

Article  PubMed  PubMed Central  Google Scholar 

Savvateeva E, Filippova M, Valuev-Elliston V, Nuralieva N, Yukina M, Troshina E, et al. Microarray-based detection of antibodies against SARS-CoV-2 proteins, common respiratory viruses and type I interferons. Viruses. 2021;13(12):2553.

Article  PubMed  PubMed Central  Google Scholar 

Vanker M, Särekannu K, Fekkar A, Jørgensen SE, Haljasmägi L, Kallaste A, et al. Autoantibodies neutralizing type III interferons are uncommon in patients with severe coronavirus disease 2019 pneumonia. J Interferon Cytokine Res. 2023;43(9):379–93.

Article  PubMed  Google Scholar 

Goncalves D, Mezidi M, Bastard P, Perret M, Saker K, Fabien N, et al. Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients. Clin Transl Immunol. 2021;10(8):e1327.

Article  Google Scholar 

van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, et al. Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19. bioRxiv. 2021 Mar 10;2021.03.09.434529.

Bruscoli S, Puzzovio PG, Zaimi M, Tiligada K, Levi-Schaffer F, Riccardi C. Glucocorticoids and COVID-19. Pharmacol Res. 2022;1(185):106511.

Article  Google Scholar 

Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384(3):238–51.

Article  PubMed  Google Scholar 

Khamis F, Al-Zakwani I, Al Hashmi S, Al Dowaiki S, Al Bahrani M, Pandak N, et al. Therapeutic plasma exchange in adults with severe COVID-19 infection. Int J Infect Dis. 2020;1(99):214–8.

Article  Google Scholar 

Beccuti G, Ghizzoni L, Cambria V, Codullo V, Sacchi P, Lovati E, et al. A COVID-19 pneumonia case report of autoimmune polyendocrine syndrome type 1 in Lombardy, Italy: letter to the editor. J Endocrinol Invest. 2020;43(8):1175–7.

Article